<DOC>
	<DOCNO>NCT00545402</DOCNO>
	<brief_summary>This 2 arm study compare efficacy safety two CellCept-containing treatment regimens de novo liver transplant patient . Patients randomize one two group , receive either CellCept ( start dose 3g/day po , adjust accord exposure ) standard dose tacrolimus corticosteroid ( 10-15 mg/kg i.v . day 0 ) , fix dose CellCept 2g/day po , standard dose tacrolimus corticosteroid ( 10-15mg/kg i.v . day 0 , reduce 20mg 5mg 6 month , discontinue 6 month ) . The anticipated time study treatment 3-12 month , target sample size 100-500 individual .</brief_summary>
	<brief_title>A Study CellCept ( Mycophenolate Mofetil ) Combination Therapy Liver Transplant Patients .</brief_title>
	<detailed_description />
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<criteria>adult patient , &gt; =18 year age ; recipient first orthotopic liver transplant . history organ transplant ; patient receive multiorgan transplant ; calculate creatinine clearance &lt; =30mL/min transplant ; leukocyte count &lt; 2000/mm3 randomization ; history cancer within past 5 year , except successfully treat basal cell squamous cell cancer , situ cervical cancer ; pregnant breastfeeding female , female childbearing age use effective contraception .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
</DOC>